A novel deal struck by Vertex and the Irish authorities will ensure reimbursement for the company’s cystic fibrosis drugs, Orkambi and Kalydeco, not only for current uses but for newly approved populations – and any new products for the same uses.
Vertex Pharmaceuticals and the Irish Health Service Executive have struck what the company describes as an “innovative” agreement that provides long-term reimbursement of Vertex Pharmaceuticals’ cystic fibrosis treatment, Orkambi (lumacaftor/ivacaftor) and expands access to the company’s other CF drug, Kalydeco (ivacaftor).
The deal will also cover any future patient populations for which the drugs are approved, as well as any new Vertex products approved for these patients
Recent and upcoming US FDA advisory committee meetings and a summary of the topics covered.
Marcus Vass and Vladimir Murovec of international law firm Osborne Clarke tell the Pink Sheet what the government's planned HDRS might mean for industry, and how it compares with the European Health Data Space.
The European Health Data Space framework will allow companies to accelerate R&D processes and identify new molecular targets faster by facilitating centralized access to certain types of high-quality data, Finland’s Orion Pharma says.
